mRNA-based influenza vaccine expands the B cell response breadth in humans
These findings reveal a key role for persistent germinal center responses in broadening the repertoire of vaccine-induced antibodies.
Effectiveness of nirsevimab immunisation on invasive pneumococcal disease in children nationwide in France: an observational cohort study
These findings suggest an additional benefit of nirsevimab implementation beyond RSV disease prevention, but further studies are needed.
Development of a multi-species luciferase-based double-antigen ELISA for the detection of antibodies against influenza A virus H5 clade 2.3.4.4b
The assay allowed sensitive and specific detection of antibodies directed against H5 hemagglutinin of clade 2.3.4.4b in a wide range of birds and mammals, including humans.
The ageing immune system and its battle with viruses
Call for tenders (HaDEA): Framework contracts to speed up the development of and access to next-generation therapeutics for infectious diseases
The scope of the call is expected to cover the development of innovative therapeutics to treat viral infections, acute respiratory distress syndrome (ARDS) or sepsis resulting from infections.
European Medicines Agency (EMA) 2025 Annual Report
The report summarises EMA's work in evaluating and monitoring human and veterinary medicines, including approval numbers for 2025.
Cross-reactive human antibody responses to H9N2 influenza virus, New York, United States, 2025
Assessed cross-reactive antibody responses to H9N2 viruses using a panel of recently collected human sera from the general population of a large metropolitan city in North America (New York City).
Seasonal vaccine-induced immunity shows preserved cross-reactivity to H3N2 subclade K in adults
Pre-existing immunity to subclade K variants was noted with seasonal influenza vaccination further boosting titres two-fold against subclade K and three-fold against the vaccine-like strain...
